Illumina Inc (ILMN) 170.65 $ILMN
SmarTrend Watching for Potential Pullback in Shares of Illumina After 1.97% Gain
Comtex SmarTrend(R) - Mon Aug 01, 2:06PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $166.13 to a high of $170.88. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $167.03 on volume of 454,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 170.65 (+4.30)
Illumina Set to Possibly Pullback After Yesterday's Rally of 1.97%
Comtex SmarTrend(R) - Mon Aug 01, 2:04PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $166.13 to a high of $170.88. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $167.03 on volume of 454,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 170.65 (+4.30)
Company News for July 28, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:10AM CDT
Companies In The News are: TWTR,APC,CB,ILMN
ILMN: 170.65 (+4.30), CB: 125.27 (+0.01), TWTR: 16.64 (unch), APC: 51.85 (-2.68)
Illumina Names Philip W. Schiller to its Board of Directors
BusinessWire - Thu Jul 28, 5:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) announced today that Philip W. Schiller has joined the company's Board of Directors. Schiller is currently Apple's Senior Vice President of Worldwide Marketing and is a member of Apple's executive team responsible for the company's product marketing, developer relations, business marketing, education marketing, international marketing and App Store programs.
ILMN: 170.65 (+4.30)
Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 119.50 (+1.53), MASI: 52.93 (-0.04), CYNO: 53.51 (-1.45), ILMN: 170.65 (+4.30)
Illumina Rises 8.29% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 27, 12:14PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $145.27 to a high of $163.08. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $152.33 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 170.65 (+4.30)
Illumina Set to Possibly Pullback After Yesterday's Rally of 8.29%
Comtex SmarTrend(R) - Wed Jul 27, 12:12PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $145.27 to a high of $163.08. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $152.33 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 170.65 (+4.30)
Apple, Illumina, Alleghany Technologies, Las Vegas Sands, and Cirrus Logic and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Jul 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ATI, CRUS, ILMN, and LVS.
ATI: 17.44 (-0.37), ILMN: 170.65 (+4.30), CRUS: 49.46 (+0.87), LVS: 50.24 (-0.41), AAPL: 106.05 (+1.84)
Illumina (ILMN) Shares Climb on Q2 Earnings and Sales Beat
Zacks Premium Research - Zacks Investment Research - Tue Jul 26, 4:42PM CDT
Here are the key takeaways from the earnings report.
ILMN: 170.65 (+4.30)
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2016
BusinessWire - Tue Jul 26, 3:05PM CDT
Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the second quarter of fiscal year 2016.
ILMN: 170.65 (+4.30)
Illumina (ILMN) to Report Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:08AM CDT
Illumina (ILMN) has a Zacks Rank #4 (Sell), which along with an ESP of 0.00% makes surprise prediction difficult.
AGN: 254.86 (+1.91), LH: 139.63 (+0.07), ILMN: 170.65 (+4.30), BMY: 76.19 (+1.38)
Illumina (ILMN) Rallies on Exact Sciences Buyout Rumor
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:53AM CDT
With this buyout, Illumina (ILMN) will gain control over Cologuard -- a FDA approved non-invasive screening test of Exact Sciences that uses stool DNA technology to detect colorectal cancer.
NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), TGTX: 5.79 (-0.12), ILMN: 170.65 (+4.30)
Illumina to Announce Second Quarter 2016 Financial Results on Tuesday, July 26, 2016
BusinessWire - Tue Jul 12, 5:30AM CDT
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2016 following the close of market on Tuesday, July 26, 2016.
ILMN: 170.65 (+4.30)
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 117.07 (+0.31), NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), ILMN: 170.65 (+4.30)
Illumina Applauds FDA's Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing
BusinessWire - Thu Jul 07, 8:20AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it supports the Food and Drug Administration (FDA) in their efforts to provide a flexible and streamlined approach to the oversight of next generation sequencing (NGS) diagnostic tests, as represented by FDA's release of two new draft guidance documents. The FDA draft guidances are part of the larger Precision Medicine Initiative announced by President Obama in his 2015 State of the Union address.
ILMN: 170.65 (+4.30)
Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina, Inc.
BusinessWire - Thu Jul 07, 8:15AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a settlement with Illumina, Inc. (Nasdaq: ILMN) that included a payment of $21 million to Enzo in an action brought in Delaware Federal District Court by Enzo alleging infringement of its U.S. Patent No. 7,064,197, entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids.
ENZ: 6.72 (-0.25), ILMN: 170.65 (+4.30)
Downgrade Alert for Illumina (ILMN)
Comtex SmarTrend(R) - Wed Jul 06, 3:26AM CDT
Illumina (NASDAQ:ILMN) was downgraded from Equal Weight to Underweight at Morgan Stanley today. The stock closed yesterday at $138.67 on volume of 2.1 million shares, above average daily volume of 1.8 million. Over the past year, Illumina has traded in a range of $25.57 to $242.37 and closed yesterday at $138.67, 442% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 1.2% while the 50-day MA has declined 0.8%.
ILMN: 170.65 (+4.30)
Illumina, Inc. (ILMN) - Product Pipeline Market Analysis Report, 2016: Radiant Insights
GlobeNewswire - Thu Jun 23, 5:39AM CDT
Illumina, Inc. (Illumina) provides sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations.
ILMN: 170.65 (+4.30)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), ILMN: 170.65 (+4.30), GHDX: 30.34 (+1.31)
Illumina Announces Initial Customer Orders for the Global Screening Array
BusinessWire - Thu Jun 16, 8:00AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12 customers for its new Infinium(R) Global Screening Array (GSA). In total, the company has received orders for more than 3 million samples of the new consortia-developed array. Initial customers include human disease researchers at The Broad Institute and deCODE Genetics, health systems Avera Health, Codigo46, Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford Health and UCLA Health System, genomic service providers Centre National de Genotypage, Human Genomics Facility HuGeF, Erasmus MC, Life and Brain, and consumer genomics company 23andMe, Inc.
ILMN: 170.65 (+4.30)
SmarTrend Watching for Potential Pullback in Shares of Illumina After 1.97% Gain
Comtex SmarTrend(R) - Mon Aug 01, 2:06PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $166.13 to a high of $170.88. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $167.03 on volume of 454,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 170.65 (+4.30)
Illumina Set to Possibly Pullback After Yesterday's Rally of 1.97%
Comtex SmarTrend(R) - Mon Aug 01, 2:04PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $166.13 to a high of $170.88. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $167.03 on volume of 454,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 170.65 (+4.30)
Company News for July 28, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:10AM CDT
Companies In The News are: TWTR,APC,CB,ILMN
ILMN: 170.65 (+4.30), CB: 125.27 (+0.01), TWTR: 16.64 (unch), APC: 51.85 (-2.68)
Illumina Names Philip W. Schiller to its Board of Directors
BusinessWire - Thu Jul 28, 5:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) announced today that Philip W. Schiller has joined the company's Board of Directors. Schiller is currently Apple's Senior Vice President of Worldwide Marketing and is a member of Apple's executive team responsible for the company's product marketing, developer relations, business marketing, education marketing, international marketing and App Store programs.
ILMN: 170.65 (+4.30)
Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 119.50 (+1.53), MASI: 52.93 (-0.04), CYNO: 53.51 (-1.45), ILMN: 170.65 (+4.30)
Illumina Rises 8.29% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 27, 12:14PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $145.27 to a high of $163.08. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $152.33 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 170.65 (+4.30)
Illumina Set to Possibly Pullback After Yesterday's Rally of 8.29%
Comtex SmarTrend(R) - Wed Jul 27, 12:12PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $145.27 to a high of $163.08. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $152.33 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 170.65 (+4.30)
Apple, Illumina, Alleghany Technologies, Las Vegas Sands, and Cirrus Logic and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Jul 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ATI, CRUS, ILMN, and LVS.
ATI: 17.44 (-0.37), ILMN: 170.65 (+4.30), CRUS: 49.46 (+0.87), LVS: 50.24 (-0.41), AAPL: 106.05 (+1.84)
Illumina (ILMN) Shares Climb on Q2 Earnings and Sales Beat
Zacks Premium Research - Zacks Investment Research - Tue Jul 26, 4:42PM CDT
Here are the key takeaways from the earnings report.
ILMN: 170.65 (+4.30)
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2016
BusinessWire - Tue Jul 26, 3:05PM CDT
Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the second quarter of fiscal year 2016.
ILMN: 170.65 (+4.30)
Illumina (ILMN) to Report Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:08AM CDT
Illumina (ILMN) has a Zacks Rank #4 (Sell), which along with an ESP of 0.00% makes surprise prediction difficult.
AGN: 254.86 (+1.91), LH: 139.63 (+0.07), ILMN: 170.65 (+4.30), BMY: 76.19 (+1.38)
Illumina (ILMN) Rallies on Exact Sciences Buyout Rumor
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:53AM CDT
With this buyout, Illumina (ILMN) will gain control over Cologuard -- a FDA approved non-invasive screening test of Exact Sciences that uses stool DNA technology to detect colorectal cancer.
NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), TGTX: 5.79 (-0.12), ILMN: 170.65 (+4.30)
Illumina to Announce Second Quarter 2016 Financial Results on Tuesday, July 26, 2016
BusinessWire - Tue Jul 12, 5:30AM CDT
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2016 following the close of market on Tuesday, July 26, 2016.
ILMN: 170.65 (+4.30)
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 117.07 (+0.31), NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), ILMN: 170.65 (+4.30)
Illumina Applauds FDA's Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing
BusinessWire - Thu Jul 07, 8:20AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it supports the Food and Drug Administration (FDA) in their efforts to provide a flexible and streamlined approach to the oversight of next generation sequencing (NGS) diagnostic tests, as represented by FDA's release of two new draft guidance documents. The FDA draft guidances are part of the larger Precision Medicine Initiative announced by President Obama in his 2015 State of the Union address.
ILMN: 170.65 (+4.30)
Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina, Inc.
BusinessWire - Thu Jul 07, 8:15AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a settlement with Illumina, Inc. (Nasdaq: ILMN) that included a payment of $21 million to Enzo in an action brought in Delaware Federal District Court by Enzo alleging infringement of its U.S. Patent No. 7,064,197, entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids.
ENZ: 6.72 (-0.25), ILMN: 170.65 (+4.30)
Downgrade Alert for Illumina (ILMN)
Comtex SmarTrend(R) - Wed Jul 06, 3:26AM CDT
Illumina (NASDAQ:ILMN) was downgraded from Equal Weight to Underweight at Morgan Stanley today. The stock closed yesterday at $138.67 on volume of 2.1 million shares, above average daily volume of 1.8 million. Over the past year, Illumina has traded in a range of $25.57 to $242.37 and closed yesterday at $138.67, 442% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 1.2% while the 50-day MA has declined 0.8%.
ILMN: 170.65 (+4.30)
Illumina, Inc. (ILMN) - Product Pipeline Market Analysis Report, 2016: Radiant Insights
GlobeNewswire - Thu Jun 23, 5:39AM CDT
Illumina, Inc. (Illumina) provides sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations.
ILMN: 170.65 (+4.30)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), ILMN: 170.65 (+4.30), GHDX: 30.34 (+1.31)
Illumina Announces Initial Customer Orders for the Global Screening Array
BusinessWire - Thu Jun 16, 8:00AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12 customers for its new Infinium(R) Global Screening Array (GSA). In total, the company has received orders for more than 3 million samples of the new consortia-developed array. Initial customers include human disease researchers at The Broad Institute and deCODE Genetics, health systems Avera Health, Codigo46, Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford Health and UCLA Health System, genomic service providers Centre National de Genotypage, Human Genomics Facility HuGeF, Erasmus MC, Life and Brain, and consumer genomics company 23andMe, Inc.
ILMN: 170.65 (+4.30)
